RxDoctor Payments Data

Mahboob Alam, MD

Interventional Cardiology · Houston, TXNPI 1831342641

Payments from drug & device makers

$1,728in general payments, 2019–2025

Across 46 payments — averaging $37.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$315
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$279
  • Boston Scientific$276
  • Medtronic$140
  • Novartis$133
  • Abiomed$131
  • plus $454 from 12 others
$315in research payments, 2019–2025

Across 2 payments — averaging $157.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$315

What the payments were for

  • Food & beverage$1,728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,728 in reported general payments places this provider in the 5th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$174,198
Medicare patients
642
Services billed
1,640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$58,392
Repatha SureclickEvolocumab33$23,386
EntrestoSacubitril/Valsartan18$23,195
XareltoRivaroxaban17$15,547
BrilintaTicagrelor11$9,121
Ranolazine ErRanolazine47$7,053
Ezetimibe115$4,596
Metoprolol Succinate119$1,866
ClopidogrelClopidogrel Bisulfate137$1,672
Atorvastatin Calcium148$1,626
Bumetanide25$1,295
Rosuvastatin Calcium80$982
Carvedilol90$975
Isosorbide Mononitrate ErIsosorbide Mononitrate68$921
Nifedipine ErNifedipine18$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$133$23,19518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →